Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection
Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection
Human papillomavirus (HPV) infection is a worldwide problem strictly linked to the
 development of cervical cancer. Persistence of the infection is one of the main factors
 responsible for the invasive progression and women diagnosed with intraepithelial squamous
 lesions are referred for further assessment and surgical treatments which are prone to
 complications. Despite this, there are several reports on the spontaneous regression of the
 infection.

 In this study the investigators will evaluate the effectiveness of a long term
 polyhexamethylene biguanide (PHMB)-based local treatment in improve the viral clearance
 reducing the time exposure to the infection and avoiding the complications associated with
 the invasive treatments currently available.

 Women diagnosed with HPV infection were randomly assigned to receive six months of treatment
 with a PHMB-based gynaecological solution (Monogin®) or to remain untreated for the same
 period of time.

 The administration of Monogin® has been performed every three days for fifteen days and then
 every fifteen days for the subsequent six months.
Inclusion Criteria:

 -  pathologic Pap smear

 -  positive "high risk" HPV DNA test

 -  positive colposcopy examination

 Exclusion Criteria:

 -  patients who had undergone wart therapy in the previous six months

 -  pregnancy

 -  invasive disease

 -  immunosuppression

 -  previous HPV vaccination